These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 2668324)
41. KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Aaboe K; Knop FK; Vilsboll T; Vølund A; Simonsen U; Deacon CF; Madsbad S; Holst JJ; Krarup T J Clin Endocrinol Metab; 2009 Feb; 94(2):603-8. PubMed ID: 19050053 [TBL] [Abstract][Full Text] [Related]
42. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects. Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W Digestion; 1992; 52(3-4):214-21. PubMed ID: 1459356 [TBL] [Abstract][Full Text] [Related]
43. The effect of increasing doses of ingested glucose on insulin and gastric inhibitory polypeptide (GIP) concentrations in man. Falko JM; Crockett SE; Cataland S; O'Dorisio TM; Kramer W; Mazzaferri EL Clin Endocrinol (Oxf); 1980 Dec; 13(6):587-93. PubMed ID: 7014042 [TBL] [Abstract][Full Text] [Related]
44. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471 [TBL] [Abstract][Full Text] [Related]
45. Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. Thondam SK; Daousi C; Wilding JP; Holst JJ; Ameen GI; Yang C; Whitmore C; Mora S; Cuthbertson DJ Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E224-E233. PubMed ID: 28073779 [TBL] [Abstract][Full Text] [Related]
46. Role of gastric inhibitory polypeptide in postprandial hyperinsulinemia of obesity. Roust LR; Stesin M; Go VL; O'Brien PC; Rizza RA; Service FJ Am J Physiol; 1988 Jun; 254(6 Pt 1):E767-74. PubMed ID: 3287953 [TBL] [Abstract][Full Text] [Related]
47. Preservation of the incretin effect after orthotopic pancreas transplantation in inbred rats. Kissler HJ; Gepp H; Schmiedl A; Schwille PO Metabolism; 1999 May; 48(5):645-50. PubMed ID: 10337868 [TBL] [Abstract][Full Text] [Related]
48. Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls. Meier JJ; Nauck MA; Kask B; Holst JJ; Deacon CF; Schmidt WE; Gallwitz B World J Gastroenterol; 2006 Mar; 12(12):1874-80. PubMed ID: 16609993 [TBL] [Abstract][Full Text] [Related]
50. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Meier JJ; Gallwitz B; Siepmann N; Holst JJ; Deacon CF; Schmidt WE; Nauck MA Diabetologia; 2003 Jun; 46(6):798-801. PubMed ID: 12764578 [TBL] [Abstract][Full Text] [Related]
51. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Toft-Nielsen M; Madsbad S; Holst JJ Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105 [TBL] [Abstract][Full Text] [Related]
52. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist. Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406 [TBL] [Abstract][Full Text] [Related]
53. The incretin effect in cats: comparison between oral glucose, lipids, and amino acids. Gilor C; Graves TK; Gilor S; Ridge TK; Weng HY; Dossin O Domest Anim Endocrinol; 2011 May; 40(4):205-12. PubMed ID: 21397435 [TBL] [Abstract][Full Text] [Related]
54. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Christensen M; Vedtofte L; Holst JJ; Vilsbøll T; Knop FK Diabetes; 2011 Dec; 60(12):3103-9. PubMed ID: 21984584 [TBL] [Abstract][Full Text] [Related]
55. Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial. Heimburger SMN; Nielsen CN; Calanna S; Holst JJ; Vilsbøll T; Knop FK; Christensen MB Diabetes Obes Metab; 2022 Jan; 24(1):142-147. PubMed ID: 34490741 [TBL] [Abstract][Full Text] [Related]
57. The effect of oral galactose on GIP and insulin secretion in man. Morgan LM; Wright JW; Marks V Diabetologia; 1979 Apr; 16(4):235-9. PubMed ID: 428694 [TBL] [Abstract][Full Text] [Related]
58. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. Christensen MB Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187 [TBL] [Abstract][Full Text] [Related]
59. Effect of graded intraduodenal glucose infusions on the release and physiological action of gastric inhibitory polypeptide. McCullough AJ; Miller LJ; Service FJ; Go VL J Clin Endocrinol Metab; 1983 Feb; 56(2):234-41. PubMed ID: 6337173 [TBL] [Abstract][Full Text] [Related]
60. The effects of porcine GIP on insulin secretion and glucose clearance in the pig. Wolffbrandt KH; Damm Jørgensen K; Moody AJ; Pedersen PC Horm Metab Res; 1986 Mar; 18(3):159-62. PubMed ID: 3516832 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]